Humacyte (HUMA) vs TuHURA Biosciences (HURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Humacyte (HUMA) over the past year, losing 26.1% versus a loss of 71.3%. Over five years, HUMA leads with a -95.4% price change compared with -99.9% for HURA. Humacyte is the larger company by market cap ($124.2 million vs $123.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | HURA |
|---|---|---|
| Share price | $0.4471 | $1.93 |
| Market cap | $124.20M | $122.99M |
| 1-day change | -5.34% | -2.53% |
| YTD return | -50.85% | +154.95% |
| 1-year return | -71.29% | -26.05% |
| 5-year return | -95.38% | -99.87% |
| EPS (TTM) | $-0.51 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.90 | $3.43 |
| 52-week low | $0.4367 | $0.41 |
| Distance from 52-week high | -76.41% | -43.73% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +264.57% | +316.58% |
| Average volume | 6.30M | 249.19K |
| Shares outstanding | 277.80M | 63.73M |
| Employees | 184 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed HUMA by 45.2 percentage points over the past year.
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
HUMA vs HURA FAQ
Which is bigger, Humacyte or TuHURA Biosciences?
Humacyte (HUMA) is larger, with a market capitalization of $124.20M compared with $122.99M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, HUMA or HURA?
HURA returned -26.05% over the past 12 months, compared with -71.29% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and TuHURA Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Humacyte and Biotechnology: Pharmaceutical Preparations for TuHURA Biosciences.